Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
Por:
Kumar, Princy, Clarke, Amanda E., Jonsson-Oldenbuettel, Celia, Deltoro, Miguel Garcia, Di Giambenedetto, Simona, Brites, Carlos, Hocqueloux, Laurent, Lu, Po-Liang, Oyee, James, Oglesby, Alan, Wynne, Brian, Jones, Bryn, Evitt, Lee A., Fox, Dainielle, Kisare, Michelle, Priest, Julie
Publicada:
1 ene 2025
Ahead of Print:
1 sep 2024
Resumen:
Patient-reported outcomes (PROs) facilitate communication between
patients and providers, enhancing patient-centered care. We report PROs
for virologically suppressed people living with HIV-1 who switched to
dolutegravir/lamivudine (DTG/3TC) or continued their 3- or 4-drug
current antiretroviral regimen (CAR) in the phase 3 SALSA study.
Secondary endpoints included change from baseline in HIV Treatment
Satisfaction Questionnaire (status version; HIVTSQs) and HIV Symptom
Distress Module (HIV-SDM) at Weeks 4, 24, and 48. A post hoc analysis
assessed change in HIVTSQs and HIV-SDM by age (>= 50 and < 50 years).
Higher HIVTSQs scores represent greater treatment satisfaction (range,
0-60); lower HIV-SDM scores indicate less symptom bother (range, 0-80).
Participants in the DTG/3TC (n = 246) and CAR (n = 247) groups reported
comparable baseline HIVTSQs total scores (mean [SD], 55.2 [6.5] and 55.8
[5.5], respectively). Beginning at Week 4, mean HIVTSQs scores in the
DTG/3TC group further increased vs. CAR and were sustained through Week
48. Baseline mean (SD) HIV-SDM symptom bother scores were comparable
between the DTG/3TC (9.0 [9.9]) and CAR (7.9 [9.3]) groups. Small
improvements in HIV-SDM scores favoring DTG/3TC were observed at Weeks 4
and 24 and sustained through Week 48 (though not significant between
groups). Participants aged >= 50 and < 50 years who switched to DTG/3TC
reported higher satisfaction and less symptom distress vs. CAR; these
results were generally comparable between age groups. Participants who
switched to DTG/3TC reported rapid and sustained improvements in
treatment satisfaction compared with those who continued CAR,
reinforcing the benefits of DTG/3TC beyond virologic suppression
(NCT04021290; registration date, 7/11/2019).
Filiaciones:
Georgetown Univ, Med Ctr, Washington, DC USA
Royal Sussex Cty Hosp, Brighton, England
Brighton & Sussex Med Sch, Brighton, England
MUC Res, MVZ Munchen Goethepl, Munich, Germany
Consortium Gen Univ Hosp Valencia, Infect Dis Serv, Valencia, Spain
Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS,
UOC Malattie Infett, Rome, Italy
Univ Fed Bahia, Salvador, Brazil
Ctr Hosp Univ Orleans, Orleans, France
Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
GSK, Brentford, England
ViiV Healthcare, Durham, NC 27701 USA
ViiV Healthcare, Brentford, England
|